Lisata Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Lisata Therapeutics

08/05/2025 22:02

Lisata Therapeutics Inc LSTA.OQ reported a quarterly adjusted loss of 55 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -65 cents.  The lone analyst forecast for the quarter was for a loss of 53 cents per share.

Reported revenue was zero​; analysts expected zero.

Lisata Therapeutics Inc's reported EPS for the quarter was a loss of 55 cents​.

The company reported a quarterly loss of $4.72 million.

Lisata Therapeutics Inc shares had fallen by 2.1% this quarter and lost 22.8% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 28.4% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Lisata Therapeutics Inc is $15.00

This summary was machine generated from LSEG data May 8 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
-0.53
-0.55
Missed
Dec. 31 2024
-0.76
-0.55
Beat
Sep. 30 2024
-0.75
-0.59
Beat
Jun. 30 2024
-0.76
-0.61
Beat